Table 5.

Factors associated with poor outcomes at 4 weeks after the initiation of immunotherapy (mRS ≥3).

	Odds ratio (95% CI)	P
Univariable analysis
Demographic data
age of onset	1.03 (0.99-1.07)	0.11
gender	0.69 (0.18-2.73)	0.60
hospital days	1.01 (0.97-1.05)	0.58
Serologic data
MLR*	1.66 (0.22-12.54)	0.63
NLR*	0.98 (0.91-1.06)	0.66
tumor marker	0.86 (0.21-3.47)	0.83
proven viral infection in serum	5.71 (1.16-28.07)	0.03
positive for non-neural autoantibodies in serum	7.50 (1.28-44.09)	0.03
CSF examination
white cells	1.002 (0.997-1.007)	0.45
protein level	1.000 (0.999-1.001)	0.66
viral antibodies in CSF	5.33 (0.53-54.03)	0.16
glucose level	1.89 (0.78-4.60)	0.16
Clinical symptoms
fever	0.91 (0.22-3.76)	0.90
hyponatremia	1.43 (0.35-5.79)	0.62
headache	0.65 (0.16-2.72)	0.56
disturbance of consciousness	3.63 (0.74-17.81)	0.11
nausea	0.83 (0.20-3.56)	0.81
vomiting	1.43 (0.35-5.79)	0.62
limb weakness	0.86 (0.21-3.47)	0.83
dizziness	5.33 (0.53-54.03)	0.16
stiff neck	1.09 (0.25-4.82)	0.91
limb numbness	1.08 (0.18-6.32)	0.94
dysuria and constipation	0.42 (0.09-2.01)	0.29
involuntary movements	3.41 (0.56-20.94)	0.19
neuropathic pain	1.08 (0.18-6.32)	0.94
psychosis	2.50 (0.39-16.05)	0.33
poor appetite	1.48 (0.32-6.90)	0.62
blurred vision	0.31 (0.03-3.35)	0.34
prodromal symptoms	0.89 (0.23-3.49)	0.87
ICU admission	1.87 (0.44-7.85)	0.39
mechanical ventilation	5.33 (0.53-54.03)	0.16
mRs at admission	1.44 (0.81-2.57)	0.21
Multivariable analysis
positive for non-neural autoantibodies in serum	17.67 (1.60-195.11)	0.02
proven viral infection in serum	11.96 (1.26-113.92)	0.03

*MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio.